Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 502982301

Cayman Chemical Loxoribine, Purity: ≥98%, CAS: 121288-39-9, 50 mg
SDP

Catalog No. 502982301
Encompass_Preferred

A guanosine derivative and an agonist of TLR7; selective for TLR7 over other human TLRs in a cell-based reporter assay at 1 mM; induces proliferation, increases the antibody response to sheep red blood cells, and activates natural killer cell activity against Yac-1 lymphoma cells in murine splenocyte cultures (EC50s = 10-50, 3-20, and 13-22 μM, respectively); increases production of IL-12, IL-23, IL-27, and IL-10 by human MoDCs at 250 μM; loxoribine-treated MoDCs induce higher levels of IL-17 and IFN-γ secretion by co-cultured allogeneic CD4+ T cells compared to control MoDCs; reduces the number of pulmonary metastases in the B16 mouse model of melanoma at 120 mg/kg, an effect enhanced by co-administration of IL-2; exhibits adjuvant activity in mice immunized with a B16 tumor vaccine

Catalog No. 50-298-2301 Supplier Cayman Chemical Supplier No. 2118650 MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

A guanosine derivative and an agonist of TLR7; selective for TLR7 over other human TLRs in a cell-based reporter assay at 1 mM; induces proliferation, increases the antibody response to sheep red blood cells, and activates natural killer cell activity against Yac-1 lymphoma cells in murine splenocyte cultures (EC50s = 10-50, 3-20, and 13-22 μM, respectively); increases production of IL-12, IL-23, IL-27, and IL-10 by human MoDCs at 250 μM; loxoribine-treated MoDCs induce higher levels of IL-17 and IFN-γ secretion by co-cultured allogeneic CD4+ T cells compared to control MoDCs; reduces the number of pulmonary metastases in the B16 mouse model of melanoma at 120 mg/kg, an effect enhanced by co-administration of IL-2; exhibits adjuvant activity in mice immunized with a B16 tumor vaccine

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.